Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.72 |
| ▸ | PTGER4 | P35408 | 10/20 | 0.61 |
| ▸ | CNR2 | P34972 | 3/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27823781 | 1.00 | CNR1 (0.72) | CNR1PTGER4CNR2PTGS1PTGS2 | |
| SCHEMBL12884870 | 0.89 | PTGER4 (0.62) | CNR1PTGER4CNR2MEN1KMT2A | |
| SCHEMBL12884868 | 0.86 | CNR1 (0.53) | CNR1PTGER4CNR2MEN1KMT2A | |
| SCHEMBL25369148 | 0.85 | CNR1 (0.71) | CNR1PTGER4CNR2PTGS1PTGS2 | |
| SCHEMBL12884556 | 0.85 | CNR1 (0.71) | CNR1PTGER4CNR2PTGS1PTGS2 | |
| SCHEMBL1217062 | 0.84 | CNR1 (1.00) | CNR1PTGER4CNR2PTGS1PTGS2 | |
| SCHEMBL29362171 | 0.84 | CNR1 (1.00) | CNR1PTGER4CNR2PTGS1PTGS2 | |
| SCHEMBL16201827 | 0.84 | CNR1 (1.00) | CNR1PTGER4CNR2PTGS1PTGS2 | |
| SCHEMBL1211442 | 0.83 | CNR1 (0.77) | CNR1PTGER4CNR2PTGS1PTGS2 | |
| SCHEMBL13688869 | 0.83 | CNR1 (0.77) | CNR1PTGER4CNR2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101977655-A | Indazole derivatives | PFIZER | 2011-02-16 | — | — | CN | disclosed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| EP-2265335-A1 | INDAZOLE DERIVATIVES | Pfizer Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009106982-A1 | INDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106982-A1 | INDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028447-A1 | INDAZOLE DERIVATIVES | CNR1, CNR2, GPR119 | CNR1 1/4885PTGER4 359/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.